Showing BioInteractions for Foreskin keratinocyte (neonatal) (DB10772)
BioInteractor utilizes data on drug-target, -enzyme and -transporter associations to provide insight on drug-drug interactions. It allows you to identify, for instance, which drugs act similarly on the same target. Such drugs may have additive pharmacodynamic effects if given concomitantly. Conversely, two drugs may antagonize the beneficial effects of each other by having opposite actions on a specific drug target. BioInteractor uses ranked drug-enzyme association information to predict enzyme-mediated drug interactions that may be clinically relevant.
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Fibroblast growth factor 1 agonist | ||
| 1 | Fibroblast growth factor 1 antagonists | Pentosan polysulfate |
| 2 | Fibroblast growth factor 1 inhibitors | Amlexanox, Pazopanib |
| 3 | Fibroblast growth factor 1 agonists | Foreskin fibroblast (neonatal) |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Epidermal growth factor receptor agonist | ||
| 1 | Epidermal growth factor receptor antagonists | Cetuximab, Erlotinib, Gefitinib, Icotinib, Lapatinib, Lidocaine, Necitumumab, Zalutumumab |
| 2 | Epidermal growth factor receptor suppressors | Panitumumab |
| 3 | Epidermal growth factor receptor inhibitors | Abivertinib, Afatinib, Brigatinib, Dacomitinib, Fostamatinib, Neratinib, Olmutinib, Osimertinib, Vandetanib, Zanubrutinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Granulocyte-macrophage colony-stimulating factor receptor subunit alpha agonist | ||
| 1 | Granulocyte-macrophage colony-stimulating factor receptor subunit alpha agonists | Foreskin fibroblast (neonatal), Sargramostim |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Interleukin-1 beta agonist | ||
| 1 | Interleukin-1 beta modulators | Minocycline |
| 2 | Interleukin-1 beta binders | Canakinumab, Rilonacept |
| 3 | Interleukin-1 beta antagonists | Gallium nitrate |
| 4 | Interleukin-1 beta inhibitors | Donepezil |
| 5 | Interleukin-1 beta inducers | Donepezil |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Interleukin-6 agonist | ||
| 1 | Interleukin-6 antagonists | Ginseng, Siltuximab |
| 2 | Interleukin-6 inhibitors | Polaprezinc |
| 3 | Interleukin-6 agonists | Foreskin fibroblast (neonatal) |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Interferon gamma agonist | ||
| 1 | Interferon gamma agonists | Foreskin fibroblast (neonatal) |
| 2 | Interferon gamma neutralizers | Emapalumab |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Fibroblast growth factor receptor 2 agonist | ||
| 1 | Fibroblast growth factor receptor 2 agonists | Foreskin fibroblast (neonatal), Palifermin |
| 2 | Fibroblast growth factor receptor 2 binders | Palifermin |
| 3 | Fibroblast growth factor receptor 2 antagonists | Thalidomide |
| 4 | Fibroblast growth factor receptor 2 inhibitors | Erdafitinib, Fostamatinib, Lenvatinib, Nintedanib, Pemigatinib, Ponatinib, Pralsetinib, Regorafenib, Selpercatinib |
| 5 | Fibroblast growth factor receptor 2 ligands | Sucrosofate |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Platelet-derived growth factor receptor alpha agonist | ||
| 1 | Platelet-derived growth factor receptor alpha inhibitors | Fostamatinib, Lenvatinib, Midostaurin, Nintedanib, Pazopanib, Ponatinib, Regorafenib, Ripretinib, Sunitinib |
| 2 | Platelet-derived growth factor receptor alpha antagonists | Imatinib, Midostaurin, Olaratumab |
| 3 | Platelet-derived growth factor receptor alpha substrates | Erdafitinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a TGF-beta receptor type-2 agonist | ||
| 1 | TGF-beta receptor type-2 agonists | Foreskin fibroblast (neonatal) |
| 2 | TGF-beta receptor type-2 inhibitors | Fostamatinib |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Transforming growth factor beta-1 agonist | ||
| 1 | Transforming growth factor beta-1 inhibitors | Hyaluronidase, Hyaluronidase (human recombinant), Hyaluronidase (ovine) |
| 2 | Transforming growth factor beta-1 agonists | Foreskin fibroblast (neonatal) |
| 3 | Transforming growth factor beta-1 inducers | Terazosin |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Tumor necrosis factor agonist | ||
| 1 | Tumor necrosis factor inhibitors | Amrinone, Chloroquine, Infliximab, Polaprezinc, Pomalidomide, Pseudoephedrine, Thalidomide |
| 2 | Tumor necrosis factor neutralizers | Certolizumab pegol |
| 3 | Tumor necrosis factor antagonists | Epinephrine, Glycyrrhizic acid |
| 4 | Tumor necrosis factor agonists | Epinephrine, Foreskin fibroblast (neonatal) |
| 5 | Tumor necrosis factor inducers | Bryostatin 1 |
| Interacting Group | Interacting Drugs | |
|---|---|---|
| Foreskin keratinocyte (neonatal) is a Vascular endothelial growth factor A agonist | ||
| 1 | Vascular endothelial growth factor A inhibitors | Brolucizumab, Dalteparin, Minocycline, Vandetanib |
| 2 | Vascular endothelial growth factor A antagonists | Faricimab, Pegaptanib |
| 3 | Vascular endothelial growth factor A binders | Aflibercept |